Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D01RDB
|
|||
| Former ID |
DNC013343
|
|||
| Drug Name |
N-[2-(1H-benzoimidazol-2-yl)-benzoyl]-guanidine
|
|||
| Synonyms |
CHEMBL233863; N-[2-(1H-benzoimidazol-2-yl)-benzoyl]-guanidine
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C15H13N5O
|
|||
| Canonical SMILES |
C1=CC=C(C(=C1)C2=NC3=CC=CC=C3N2)C(=O)N=C(N)N
|
|||
| InChI |
1S/C15H13N5O/c16-15(17)20-14(21)10-6-2-1-5-9(10)13-18-11-7-3-4-8-12(11)19-13/h1-8H,(H,18,19)(H4,16,17,20,21)
|
|||
| InChIKey |
FJRZRURKRDCIKZ-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Sodium/hydrogen exchanger 1 (SLC9A1) | Target Info | Inhibitor | [1] |
| KEGG Pathway | cAMP signaling pathway | |||
| Cardiac muscle contraction | ||||
| Adrenergic signaling in cardiomyocytes | ||||
| Regulation of actin cytoskeleton | ||||
| Thyroid hormone signaling pathway | ||||
| Salivary secretion | ||||
| Gastric acid secretion | ||||
| Pancreatic secretion | ||||
| Bile secretion | ||||
| Proteoglycans in cancer | ||||
| Pathway Interaction Database | Endothelins | |||
| RhoA signaling pathway | ||||
| ErbB1 downstream signaling | ||||
| Signaling mediated by p38-alpha and p38-beta | ||||
| Reactome | Hyaluronan uptake and degradation | |||
| WikiPathways | Regulation of Actin Cytoskeleton | |||
| G Protein Signaling Pathways | ||||
| Glycosaminoglycan metabolism | ||||
| Osteoclast Signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Benzimidazol-2-yl or benzimidazol-2-ylthiomethyl benzoylguanidines as novel Na+/H+ exchanger inhibitors, synthesis and protection against ischemic-... Bioorg Med Chem Lett. 2007 May 1;17(9):2430-3. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.